The Netherlands And Seattle
LEIDEN, The Netherlands and SEATTLE, May 3, 2011 - ProFibrix B.V., a leader in the development of innovative
products that help stop bleeding (hemostasis) after surgery, today announced
the successful closing of a series B follow-on financing.
LEIDEN, The Netherlands and SEATTLE, March 8, 2011 - ProFibrix B.V., a leader in the development of innovative
products for hemostasis, today announced that it has initiated a prospective,
multi-center Phase II study with its lead product Fibrocaps at up to 20
sites, including major U.S.
LEIDEN, The Netherlands and SEATTLE, June 17, 2010 - ProFibrix B.V., a leader in the development of innovative
products for hemostasis and regenerative medicine, today announced that it
has entered into an agreement with CSL Behring for the clinical and
commercial supply of plasma-based fibrinogen and thrombin, for the
manufacturing of Fibrocaps(TM).
LEIDEN, The Netherlands and SEATTLE, Washington, March 11, 2010 - ProFibrix B.V., a leader in the development of innovative
products for hemostasis and regenerative medicine, today announced the
conclusion of the first Phase II trial testing its unique new hemostat
Fibrocaps(TM).
LEIDEN, The Netherlands and SEATTLE, Washington, January 7 - ProFibrix B.V., a leader in the development of innovative
products for hemostasis and regenerative medicine, today announced that
SenterNovem, an agency of the Dutch Ministry of Economic Affairs, has granted
the company a loan under its new Innovation Credit scheme of potentially up
to EUR 5 million to finance the further clinical development of its unique
new hemostat Fibrocaps(TM).
